Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Journal of the National Comprehensive Cancer Network : JNCCN - 20(2022), 8 vom: 06. Aug., Seite 925-951 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Haddad, Robert I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.08.2022 Date Revised 21.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.6004/jnccn.2022.0040 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344673898 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344673898 | ||
| 003 | DE-627 | ||
| 005 | 20231226023324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.6004/jnccn.2022.0040 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344673898 | ||
| 035 | |a (NLM)35948029 | ||
| 035 | |a (PII)jnccn2008gls | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Haddad, Robert I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2022 | ||
| 500 | |a Date Revised 21.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Iodine Radioisotopes |2 NLM | |
| 650 | 7 | |a Iodine |2 NLM | |
| 650 | 7 | |a 9679TC07X4 |2 NLM | |
| 700 | 1 | |a Bischoff, Lindsay |e verfasserin |4 aut | |
| 700 | 1 | |a Ball, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Bernet, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Blomain, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Busaidy, Naifa Lamki |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Dickson, Paxton |e verfasserin |4 aut | |
| 700 | 1 | |a Duh, Quan-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Ehya, Hormoz |e verfasserin |4 aut | |
| 700 | 1 | |a Goldner, Whitney S |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Theresa |e verfasserin |4 aut | |
| 700 | 1 | |a Haymart, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Holt, Shelby |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Jason P |e verfasserin |4 aut | |
| 700 | 1 | |a Iagaru, Andrei |e verfasserin |4 aut | |
| 700 | 1 | |a Kandeel, Fouad |e verfasserin |4 aut | |
| 700 | 1 | |a Lamonica, Dominick M |e verfasserin |4 aut | |
| 700 | 1 | |a Mandel, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Markovina, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a McIver, Bryan |e verfasserin |4 aut | |
| 700 | 1 | |a Raeburn, Christopher D |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaee, Rod |e verfasserin |4 aut | |
| 700 | 1 | |a Ridge, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Roth, Mara Y |e verfasserin |4 aut | |
| 700 | 1 | |a Scheri, Randall P |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Jatin P |e verfasserin |4 aut | |
| 700 | 1 | |a Sipos, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Sippel, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Sturgeon, Cord |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Thomas N |e verfasserin |4 aut | |
| 700 | 1 | |a Wirth, Lori J |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Yeh, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Cassara, Carly J |e verfasserin |4 aut | |
| 700 | 1 | |a Darlow, Susan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the National Comprehensive Cancer Network : JNCCN |d 2003 |g 20(2022), 8 vom: 06. Aug., Seite 925-951 |w (DE-627)NLM156397676 |x 1540-1413 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:8 |g day:06 |g month:08 |g pages:925-951 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.6004/jnccn.2022.0040 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2022 |e 8 |b 06 |c 08 |h 925-951 | ||